Shares of StemCells (STEM) Pop as First Spinal Cord Patient Enrolls in Phase I/II Trial
Tweet Send to a Friend
StemCells, Inc. (Nasdaq: STEM) today announced that the first patient with an incomplete spinal cord injury has been enrolled in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
